Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocrystalline megestrol acetate vs placebo for anorexia in unresectable hepatocellular carcinoma receiving TACE plus targeted and immunotherapy
ChiCTR2600117241Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC), cancer anorexia-cachexia syndrome (CACS), anorexia nervosa (AN) and 1 more comparing Megestrol acetate group with Placebo group (2 arms). Primary endpoint: Proportion of patients with >5% weight loss from baseline at Week 12. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
megestrol
03
Conditions
hepatocellular carcinoma (HCC)cancer anorexia-cachexia syndrome (CACS)anorexia nervosa (AN)Malnutrition
Beyond the preview
Go deeper on ChiCTR2600117241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117241.